Traws Pharma Announces Conference Call for Financial Results
Traws Pharma, Inc. (NASDAQ: TRAW), known for its innovative approach to combating respiratory viral diseases, is preparing to share its financial results for the second quarter. This announcement was made just ahead of the scheduled conference call and webcast, which will provide insights into the company's progress and its future direction.
Details of the Upcoming Call
The conference call is set for Thursday at 8:30 AM ET. Participants can join in by dialing in from the U.S. at 1-877-407-0789 or internationally at 1-201-689-8562. Major points of discussion will include Traws' financial performance for the quarter ending June 30, recent developments in the company's projects, and future outlook. Attendees will need the conference ID, which is 13754425, to join the discussion.
Webcast Access
For those interested in a more visual format, an online webcast will also be available. Interested parties can access the livestream through Traws Pharma's investor portal. Following the event, a replay will be accessible as well, allowing everyone to catch up on the insights shared.
Understanding Traws Pharma's Mission
Traws Pharma operates at the forefront of biopharmaceutical development, focusing on therapies that address urgent health threats posed by respiratory viral diseases. The company employs a unique integration of antiviral drug development, medical intelligence, and regulatory strategy, which positions it well to tackle challenges in treating resistant virus strains.
Current Projects in Development
The highlight of Traws Pharma's portfolio includes several investigational oral antiviral agents. These novel treatments are designed to counteract challenging viruses such as those causing bird flu, seasonal influenza, and ongoing issues related to COVID-19 and Long COVID. One of the promising candidates, Tivoxavir marboxil, is being developed as a single-dose treatment for influenzas, while Ratutrelvir seeks to provide an effective COVID treatment option.
Partnership Opportunities
In addition to its antiviral pipeline, Traws Pharma is actively pursuing partnerships for its clinical oncology projects, including the development of rigosertib and narazaciclib. With the expansion of their portfolio, Traws is looking to collaborate with other entities to enhance the reach and effectiveness of its offerings.
Corporate Information and Contact
For more details about Traws Pharma's initiatives and upcoming events, investors and interested parties are encouraged to visit the company's official website. There, visitors can find further information about partnership opportunities and the ongoing evolution of their clinical programs.
Contact Information:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
Website: www.trawspharma.com
Investor Relations Contact:
John Fraunces
LifeSci Advisors, LLC
Phone: 917-355-2395
Email: jfraunces@lifesciadvisors.com
Frequently Asked Questions
What significant updates will Traws Pharma share in the call?
Traws Pharma plans to discuss their financial performance and advancements in clinical projects, providing insight into their ongoing work in antiviral therapies.
How can I access the webcast?
The webcast can be accessed through Traws Pharma's official investor portal, where a replay will also be made available post-event.
What is Traws Pharma's primary focus?
The company is dedicated to developing novel therapies aimed at addressing significant health threats from respiratory viral infections.
Are there partnership opportunities with Traws Pharma?
Yes, Traws Pharma is actively seeking partnerships for their clinical oncology programs, and interested parties can find more information on their website.
How do I contact Traws Pharma for more information?
You can contact Charles Parker via email at cparker@trawspharma.com for any inquiries regarding the company.
